EL102 – a new strategy for targeting hypoxia-driven cancer

Background: EL102, a novel toluidine sulphonamide, is an orally available small molecule inhibitor of HIF1 a induced hypoxic signaling pathways. It is a dual-inhibitor of apoptosis and angiogenesis and positively tested for prostate cancer and multiple myeloma cells. EL102 directly inhibits the androgen -, progesterone -, adenosine 3A receptor and tubulin. Methods: We screened 5 human gastric and 6 colorectal cancer cell lines and a human melanoma cell line as positive control by RT-PCR for these target structures. We analyzed the effects of single incubation of EL102 and combinations with cytotoxic drugs in the…